SMED Clinical Research

Executive Summary

SMED Clinical Research, founded in 2024 by Dr. Sonia Maciá in Barcelona, is a young contract research organization (CRO) that combines traditional clinical trial management with advanced artificial intelligence and machine learning capabilities. The company offers strategic advisory, protocol development, and full-service trial management across multiple therapeutic areas, with a stated goal of leveraging AI for data analysis and biomarker discovery. Despite its early stage—with no disclosed funding, employee count, or revenue—SMED aims to differentiate itself through technology-driven efficiency and global reach. The CRO operates as a private entity and has not yet established a track record of completed trials or key partnerships. Given its recent founding and lack of public milestones, SMED Clinical Research is in a nascent phase with limited visibility. The company's focus on AI in clinical research aligns with industry trends, but it faces significant competition from established CROs and technology firms. Conviction in the company's near-term impact is low due to the absence of financial data, client endorsements, or specific project wins. However, the innovative approach and the founder's expertise could position it for growth if it successfully executes on its strategy.

Upcoming Catalysts (preview)

• Q3 2026First Major Client Contract or Partnership40% success
• Q4 2026Launch of Proprietary AI Platform for Trial Optimization30% success
• TBDRegulatory Clearance or Accreditation (e.g., ISO 27001)50% success